SequelSEC

TELA Bio, Inc. TELA

Surgical & Medical Instruments & Apparatus · CIK 0001561921 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$79.91M
Fiscal year ended 2026-06-30
Operating income
-$34.01M
Fiscal year ended 2026-06-30
Free cash flow
-$31.62M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$76.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.72Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity12.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity8.82x98th
CapEx / revenue0.6%10th
Gross margin67.7%66th
Current ratio4.20x63th
FCF margin-35.7%37th
Net margin-48.4%38th
Operating margin-42.0%41th
Revenue YoY growth15.8%55th
SBC / revenue4.7%46th
R&D / revenue11.5%48th

TELA Bio, Inc. (TELA) reported revenue of $79.91M and net income of -$41.18M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TELA Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

TELA Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$79.91M
Cost of revenueUnavailable
Gross profit$54.19M
Operating income-$34.01M
Net income-$41.18M
Research & development$9.54M
Weighted-average diluted sharesUnavailable
Pretax income-$40.91M
Income tax expense$265.00K
Diluted EPSUnavailable
Selling, general & administrative$78.66M
General & administrative$15.96M
Selling & marketing$62.70M

Balance

TELA Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$30.42M
Total assets$59.74M
Current assets$54.49M
Total liabilities$75.60M
Current liabilities$18.22M
Total equity incl. NCI-$15.87M
Temporary (mezzanine) equityUnavailable
Inventory$11.06M
Accounts receivable$9.64M
GoodwillUnavailable
Long-term debt$56.08M
Accounts payable$2.88M

Cash flow

TELA Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$31.14M
Capital expenditures$480.00K
Investing cash flow$933.00K
Financing cash flow$25.56M
Net change in cash-$4.62M
Stock-based compensation$3.20M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

TELA Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$31.62M
Gross margin67.8%
Operating margin-42.6%
FCF margin-39.6%
SBC / revenue4.0%
Current ratio2.99x
Revenue YoY growth6.1%
Net margin-51.5%
R&D / revenue11.9%
CapEx / revenue0.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TELA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.